FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136919928> ?p ?o ?g. }

• W3136919928 abstract "Lung cancer is currently the leading cause of cancer death in both developing and developed countries. Given that lung cancer has poor prognosis in later stages, it is essential to achieve an early diagnosis to maximise a patient’s overall survival. Lung adenocarcinoma (LUAD), a subtype of non-small cell lung cancer (NSCLC), has the highest incidence in both smokers and non-smokers. Therefore, there is an urgent need to develop methods to provide both sensitive and specific lung cancer diagnosis.The current standard and non-invasive screening method, low‐dose computed tomography (LDCT), is the only radiological method which shows to have mortality benefits from multiple large randomized clinical trials (RCT). However, these RCTs also found LDCT to have a significant false positive rate of 96% which resulted in unnecessary invasive biopsies being performed. Due to the lack of sensitive and specific screening methods for the early detection of lung cancer, there is an urgent need for alternative biomarkers that are minimally invasive and may provide diagnostic, and/or prognostic potential. Circulating biomarkers can be readily detectable in blood and have been extensively studied as prognosis markers. Circulating microRNA (miRNA) been investigated for these purposes as an augmentation to LDCT, or as direct diagnosis of lung cancer. There is however, a lack of consensus across the studies on what miRNAs are the most clinically useful.   In steps to address this problem, we performed a comprehensive unbiased assessment of all known miRNAs in a progression series of 25 human LUAD tissues. In the microarray data, we identified four novel findings. Firstly, we identified 13 miRNAs with differential expression changes across all four stages of LUAD tissue. Secondly, these 13 miRNAs include miR-4454, miR-4634 miR-4707-5p, and miR-4492, which have not been reported in previous literature related to early LUAD. Thirdly, three of the 13 miRNAs: miR-96-5p, miR-182-5p, and miR-183-5p also show a strong correlation between LUAD disease progression and expression level. Finally, we identified miR-31-5p as the strongest correlation with LUAD stage progression out of all the miRNAs investigated in our dataset.We validated the microarray expression of miR-31-5p, miR-96-5p, miR-182-5p, and miR-183-5p expression level by quantitative real time polymerase chain reaction (qRT-PCR) in the 25 LUAD tissues present on the array. Next, to confirm that miRNA expression may be related early stage LUAD, we obtained an independent cohort of stage I LUAD (n=23) and 11 adjacent normal tissues. Real-time qPCR confirmed that all four miRNAs’ expression level were significantly upregulated (P≤0.05) in stage I LUAD with miR-31-5p increasing by ~35-fold, miR-96-5p by ~8-fold, miR-182-5p by ~5-fold, and miR-183-5p by ~6-fold.Next, to explore the notion that the miRNA panel may serve as circulating biomarkers for early detection and/or prognosis, we obtained plasma samples from 56 patients (32 Stage I, 5 Stage II, 8 Stage III, and 5 Stage IV) with LUAD along with six healthy control samples (this set includes 26 samples which had a matched  tissue sample). As previously observed in stage I tissue, the circulating expression levels of miR-31-5p, miR-182-5p, and miR-183-5p were significantly increased. Interestingly, miR-96-5p expression was only detected in three out of 56 plasma samples and was deemed not to be a robust biomarker. As such, only the diagnostic utility of miR-31-5p, miR-182-5p, and miR-183-5p were investigated further. The receiver operator curve (ROC) area under the curve (AUC) of miR-31-5p, miR-182-5p, miR-183-5p ranged from 0.8750 - 0.8229 when stage I was compared with normal controls. Similar AUC scores were observed when stage II tissues were investigated. Therefore, these three miRNAs may have diagnostic utility for early detection of LUAD in plasma which warrants further investigation.In summary, we have identified miR-4454, miR-4707-5p, miR-4492, and miR-4634 as novel miRNA related to LUAD from the microarray. Moreover, miR-31-5p, miR-96-5p, miR-182-5p, and miR-183-5p tissue expression level have a strong correlation with LUAD disease progression. Finally, plasma miR-31-5p, miR-182-5p, and miR-183-5p have non-invasive diagnostic utility individually in early staged LUAD." @default.
• W3136919928 created "2021-03-29" @default.
• W3136919928 creator A5024204601 @default.
• W3136919928 date "2020-10-28" @default.
• W3136919928 modified "2023-10-16" @default.
• W3136919928 title "Identification of clinically useful plasma miRNA as minimally invasive biomarkers for early stage Non-Small Cell Lung Carcinoma (NSCLC)" @default.
• W3136919928 cites W130099911 @default.
• W3136919928 cites W142392737 @default.
• W3136919928 cites W1511566179 @default.
• W3136919928 cites W1534217870 @default.
• W3136919928 cites W1602431894 @default.
• W3136919928 cites W1704321731 @default.
• W3136919928 cites W1829208371 @default.
• W3136919928 cites W1874402154 @default.
• W3136919928 cites W1916543860 @default.
• W3136919928 cites W1945206195 @default.
• W3136919928 cites W1976497891 @default.
• W3136919928 cites W1977066847 @default.
• W3136919928 cites W1979587260 @default.
• W3136919928 cites W1980032252 @default.
• W3136919928 cites W1983466841 @default.
• W3136919928 cites W1986365556 @default.
• W3136919928 cites W1988827171 @default.
• W3136919928 cites W1998413047 @default.
• W3136919928 cites W2000093333 @default.
• W3136919928 cites W2000824734 @default.
• W3136919928 cites W2006797972 @default.
• W3136919928 cites W2013099965 @default.
• W3136919928 cites W2017922974 @default.
• W3136919928 cites W2018404797 @default.
• W3136919928 cites W2019858243 @default.
• W3136919928 cites W2022557163 @default.
• W3136919928 cites W2024206172 @default.
• W3136919928 cites W2027658502 @default.
• W3136919928 cites W2030994794 @default.
• W3136919928 cites W2034752670 @default.
• W3136919928 cites W2037411879 @default.
• W3136919928 cites W2040695716 @default.
• W3136919928 cites W2048330556 @default.
• W3136919928 cites W2051240173 @default.
• W3136919928 cites W2054841768 @default.
• W3136919928 cites W2057419005 @default.
• W3136919928 cites W2059266855 @default.
• W3136919928 cites W2064165694 @default.
• W3136919928 cites W2073214067 @default.
• W3136919928 cites W2073341747 @default.
• W3136919928 cites W2074689365 @default.
• W3136919928 cites W2075321890 @default.
• W3136919928 cites W2075329854 @default.
• W3136919928 cites W2077294080 @default.
• W3136919928 cites W2077447792 @default.
• W3136919928 cites W2082188504 @default.
• W3136919928 cites W2091217268 @default.
• W3136919928 cites W2094129713 @default.
• W3136919928 cites W2098837501 @default.
• W3136919928 cites W2102326716 @default.
• W3136919928 cites W2102397321 @default.
• W3136919928 cites W2103077070 @default.
• W3136919928 cites W2103950317 @default.
• W3136919928 cites W2107277218 @default.
• W3136919928 cites W2110576880 @default.
• W3136919928 cites W2114948651 @default.
• W3136919928 cites W2116587853 @default.
• W3136919928 cites W2116636854 @default.
• W3136919928 cites W2119932227 @default.
• W3136919928 cites W2120294133 @default.
• W3136919928 cites W2121040919 @default.
• W3136919928 cites W2122936729 @default.
• W3136919928 cites W2129099526 @default.
• W3136919928 cites W2130813048 @default.
• W3136919928 cites W2134823582 @default.
• W3136919928 cites W2136605121 @default.
• W3136919928 cites W2139461628 @default.
• W3136919928 cites W2140775205 @default.
• W3136919928 cites W2141549067 @default.
• W3136919928 cites W2142249527 @default.
• W3136919928 cites W2149966907 @default.
• W3136919928 cites W2153888645 @default.
• W3136919928 cites W2162786929 @default.
• W3136919928 cites W2166317395 @default.
• W3136919928 cites W2166542986 @default.
• W3136919928 cites W2167900038 @default.
• W3136919928 cites W2177251274 @default.
• W3136919928 cites W2188371844 @default.
• W3136919928 cites W2198641492 @default.
• W3136919928 cites W2200539646 @default.
• W3136919928 cites W2207322260 @default.
• W3136919928 cites W2210138065 @default.
• W3136919928 cites W2224319365 @default.
• W3136919928 cites W2228221433 @default.
• W3136919928 cites W2257993531 @default.
• W3136919928 cites W2261581612 @default.
• W3136919928 cites W2275678839 @default.
• W3136919928 cites W2277006738 @default.
• W3136919928 cites W2286975092 @default.
• W3136919928 cites W2288117658 @default.
• W3136919928 cites W2293841445 @default.
• W3136919928 cites W2313222841 @default.
• W3136919928 cites W2336990224 @default.
• W3136919928 cites W2339886595 @default.

• next